Press Detail

• Presentations highlight Nutcracker Therapeutics' proprietary end-to-end microfluidic platform enabling rapid manufacturing of personalized cancer therapeutics

EMERYVILLE, Calif. — May 1, 2025 — Nutcracker Therapeutics, Inc., a contract, research,
development and manufacturing organization (CRDMO) with a next ​generation RNA precision
manufacturing platform, today announced its participation in two premier industry events this
May: the 3rd mRNA Process Development & Manufacturing Summit Europe in Berlin and the
2025 TIDES USA Conference in San Diego. The company will also serve as an Official
Expertise Partner for the Process Development & Manufacturing Summit Europe and an
Associate Sponsor of TIDES USA.

3rd mRNA Process Development & Manufacturing Summit Europe

Location: Hotel Palace Berlin, Berlin, Germany
Dates: May 6–8, 2025

Nutcracker Therapeutics’ Director of Biochip Research and Development, Babak Sanii, will
present the company’s approach to rapid, personalized mRNA manufacturing using its
proprietary NMU-Symphony™ platform. The talk will highlight how the company’s fully
integrated, end-to-end microfluidic manufacturing process enables the production of
personalized cancer therapies (PCTs) in as little as three weeks — from RNA design to patient-
ready injectable vials. The use of single-use biochips ensures a closed, sterile system that
eliminates the risk of patient-to-patient cross-contamination, supporting both scalability and
safety in PCTs.

Presentation Title: End-to-End Microfluidic Manufacturing of Personalized Cancer Treatments

• Presenter: Babak Sanii, director of biochip research and development
• Date & Time: May 8, 2025, at 2:00 PM (local time)
• Session: Scaling mRNA Manufacturing: Seamless Transitions from Lab to Market to Ensure Consistent Quality for Meeting Growing mRNA Vaccine & Therapeutic Demands

2025 TIDES USA

• Location: Manchester Grand Hyatt San Diego, San Diego, CA
• Dates: May 19–22, 2025

At TIDES USA, Colin McKinlay, senior director of chemistry and delivery technologies, will
showcase Nutcracker Therapeutics’ suite of proprietary technologies, including BaseCracker™
for antigen construct design, CodonCracker™ for RNA sequence optimization, and its novel
Nutshell® delivery vehicles — all key elements in assembling PCTs. These tools are seamlessly integrated into NMU-Symphony, which enables fully enclosed synthesis of RNA drugs with
quality, speed, and scalability.

Presentation Title: mRNA Manufacturing on the NMU-Symphony™ — A Rapid End-to-end
Platform for the Design, Microfluidic Synthesis, and Delivery of Personalized Cancer
Therapeutics

• Presenter: Colin McKinlay, senior director, chemistry and delivery technologies
• Date & Time: May 21, 2025, at 1:30 PM (local time)

For more information about these conferences, please visit the mRNA Process Development
and Manufacturing Summit Europe and the TIDES USA websites. In addition, please visit
Nutcracker Therapeutics’ CRDMO webpage for more information about its services.

About Nutcracker Therapeutics, Inc.

Nutcracker Therapeutics, Inc. is a biotechnology CRDMO company that combines advanced
engineering with high-precision biosynthesis to unlock the promise of RNA. The company’s
mission is to drive forward the development of safe and effective RNA drugs and personalized
cancer therapeutics through its complete technology platform, which encompasses the design,
delivery, and manufacturing of RNA molecules. Armed with this high-tech advantage,
Nutcracker Therapeutics’ unique scalable RNA platform significantly reduces costs and cycle
times, while keeping the highest quality.

For more information, visit www.nutcrackerx.com.

Media Contact:

Maggie Williard
HDMZ
Nutcrackerpr@hdmz.com